Abratt R P
Head of Clinical Governance, Independent Clinical Oncology Network, South Africa; Emeritus Professor of Radiation Oncology, Faculty of Health Sciences, University of Cape Town, South Africa.
S Afr Med J. 2016 Sep 23;106(10):981-982. doi: 10.7196/SAMJ.2016.v106i10.11141.
The drug cost of adjuvant trastuzumab to benefit one patient with localised human epidermal growth factor receptor 2 (HER2)-positive breast cancer depends on the baseline survival rate (BLSR) of the prognostic group of the patient. This varies from ZAR13 752 900 (BLSR 90%) to ZAR4 006 100 (BLSR 60%). All treated patients are exposed to potential toxicity. The value and affordability of treatments need to be considered, as there are finite resources available in our healthcare system. All patients must have access to cost-effective treatments. However, patient selection for expensive treatments is important, as expenditure on patients where the gains are relatively small will result in resources not being available for other patients. The state, healthcare institutions and the pharmaceutical industry need to work together to optimise the benefits of treatment to patients.
辅助性曲妥珠单抗使一名局部人表皮生长因子受体2（HER2）阳性乳腺癌患者受益的药物成本取决于该患者预后组的基线生存率（BLSR）。这一成本从13752900南非兰特（BLSR为90%）到4006100南非兰特（BLSR为60%）不等。所有接受治疗的患者都面临潜在毒性。由于我们的医疗保健系统资源有限，需要考虑治疗的价值和可承受性。所有患者都必须能够获得具有成本效益的治疗。然而，对于昂贵治疗的患者选择很重要，因为在获益相对较小的患者身上的支出将导致其他患者无法获得资源。国家、医疗机构和制药行业需要共同努力，以优化对患者的治疗效益。
